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Simple Summary: Breast cancer accounts as the most extended disease among women worldwide.
Store-operated calcium entry (SOCE), a major mechanism that allows calcium entry from the extracel-
lular region through the plasma membrane, is required for several physiological processes. In recent
years, it has been revealed that several breast cancer types present dysregulated calcium homeostasis,
which contribute to their malignancy. Here we show the role of two important regulators of SOCE,
SARAF and EFHB, which are necessary for cell viability, proliferation, and migration in breast cancer
and pre-neoplastic cells, respectively, thus suggesting that these regulators play a key function in
breast cancer development and progression.
Abstract: Breast cancer is among the most common malignancies in women. From the molecular
point of view, breast cancer can be grouped into different categories, including the luminal (estrogen
receptor positive (ER+)) and triple negative subtypes, which show distinctive features and, thus,
are sensitive to different therapies. Breast cancer cells are strongly dependent on Ca2+ influx. Store-
operated Ca2+ entry (SOCE) has been found to support a variety of cancer hallmarks including cell
viability, proliferation, migration, and metastasis. The Ca2+ channels of the Orai family and the
endoplasmic reticulum Ca2+ sensor STIM1 are the essential components of SOCE, but the extent
of Ca2+ influx is fine-tuned by several regulatory proteins, such as the STIM1 modulators SARAF
and EFHB. Here, we show that the expression and/or function of SARAF and EFHB is altered in
breast cancer cells and both proteins are required for cell proliferation, migration, and viability.
EFHB expression is upregulated in luminal and triple negative breast cancer (TNBC) cells and is
essential for full SOCE in these cells. SARAF expression was found to be similar in breast cancer and
pre-neoplastic breast epithelial cells, and SARAF knockdown was found to result in enhanced SOCE
in pre-neoplastic and TNBC cells. Interestingly, silencing SARAF expression in ER+ MCF7 cells led to
attenuation of SOCE, thus suggesting a distinctive role for SARAF in this cell type. Finally, we used a
combination of approaches to show that molecular knockdown of SARAF and EFHB significantly
attenuates the ability of breast cancer cells to proliferate and migrate, as well as cell viability. In
aggregate, SARAF and EFHB are required for the fine modulation of SOCE in breast cancer cells and
play an important role in the maintenance of proliferation, migration, and viability in these cells.
Keywords: EFHB; SARAF; breast cancer cells; viability; migration; calcium entry
1. Introduction
Store-operated Ca2+ entry (SOCE), a mechanism for Ca2+ influx regulated by the
filling state of the intracellular Ca2+ stores, is involved in the activation of cellular functions
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ranging from secretion to gene transcription, and dysregulation of this pathway has been
associated to different disorders, including cancer [1]. Cancer cells are characterized
by shifting the cell cycle control towards enhanced proliferation while suppressing cell
death [2]. The mechanisms underlying these changes involve up- or downregulation of a
variety of Ca2+ channels and regulatory proteins, including those involved in SOCE. The
essential elements of SOCE are the Ca2+ release-activated Ca2+ (CRAC) channels, consisting
of homo- or heterohexamers of Orai proteins [3,4], and the endoplasmic reticulum Ca2+
sensors, STIM1 and STIM2 [5–8]. Breast cancer is among the most common cancer types in
women. In breast cancer cells, Orai1 and TRPC6 are upregulated in the estrogen receptor
positive (ER+) and triple negative subtypes, and Orai3 is overexpressed exclusively in
the ER+ breast cancer subtype [9,10]. SOCE through (or facilitated by) these channels has
been reported to be critical for the development of a variety of breast cancer hallmarks,
including cell proliferation, migration, and metastasis [9–12].
In addition to the key molecular players, a variety of regulatory proteins contribute to
fine tune SOCE to match the Ca2+ responses to the strength of agonist stimulation. Among
the SOCE regulatory proteins, SARAF has been identified as a negative STIM1 modulator
that protects cells from Ca2+ overload [13]. SARAF is a 339-amino acid transmembrane
protein that interacts with STIM1 at rest to prevent spontaneous activation of SOCE, but
has also been found to be responsible for slow Ca2+-dependent inactivation (SCDI) of
CRAC channels [13,14]. SARAF is predominantly expressed in the endoplasmic reticulum
(ER) [13] but a pool is constitutively expressed in the plasma membrane where SARAF
negatively modulates a Ca2+ influx evoked by arachidonate [15]. SARAF has also been
found to modulate the activity of Orai1 and TRPC1 in a STIM1-independent manner,
potentiating Ca2+ influx through the former [16] and playing a negative regulatory role
in TRPC1-mediated Ca2+ entry [17]. In neuroblastoma cells, SARAF has been reported to
modulate the ability of arachidonate to promote cell survival [15]. Furthermore, SARAF
interacts with Orai1 in endothelial cells and contributes to the activation of angiogene-
sis [18]. SARAF interacts with the STIM1 SOAR region by a mechanism modulated by
the SOAR C-terminal inhibitory domain (CTID). CTID is located downstream the SOAR
region and consists of two lobes: the N-terminal CTID lobe (aa 448–490), which restricts
the STIM1-SARAF interaction, and the C-terminal lobe (aa 490–530), which facilitates the
interaction [14].
CRAC channel inactivation by SARAF is impaired by cell loading with the fast intracel-
lular Ca2+ chelator BAPTA, thus indicating that the role of SARAF depends on the presence
of free cytosolic Ca2+ [13]; however, SARAF does not contain Ca2+-binding domains. We
recently identified an EF-hand containing protein, an EF-hand domain family member B
(EFHB), which might act as a Ca2+ sensor regulating the interaction between STIM1 and
SARAF. EFHB is an 833-amino acid cytosolic protein that exhibits two EF-hand domains
and is essential for the STIM1–Orai1 interaction and full SOCE activation. Upon Ca2+
store depletion, EFHB interacts with STIM1 and displaces SARAF, thus allowing STIM1 to
interact with and activate CRAC channels in the plasma membrane. Then, a Ca2+ influx
induces the dissociation of STIM1 from EFHB and its re-association with SARAF to mediate
SCDI [19]. In the interactive database (www.proteinatlas.org, accessed on 18 June 2021),
both EFHB and SARAF proteins, but mostly the latter, are detected at the RNA level in
breast tissue and breast cancer samples, but protein expression has not been analyzed.
In the present study, we have investigated the role of SARAF and EFHB in SOCE
in ER+ and triple negative breast cancer (TNBC) cells. Here, we show that SARAF and
EFHB are expressed in neoplastic and pre-neoplastic breast cells, with breast cancer cells
showing upregulation of EFHB expression. Both proteins play an important role in SOCE
in neoplastic and pre-neoplastic cells and are essential for breast cancer cell survival,
proliferation, and migration. These findings provide new insights into the mechanism
regulating Ca2+ influx in breast cancer cells and its functional role.
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2. Results
2.1. Expression of EFHB and SARAF, and Functional Role in SOCE, in Breast Cancer and
Pre-Neoplastic Epithelial Cells
To investigate the possible functional role of EFHB and SARAF in breast neoplastic and
pre-neoplastic cells, we first analyze the expression of these proteins in the pre-neoplastic
breast epithelial MCF10A cell line as well as in the estrogen receptor positive (ER+) breast
cancer MCF7 cell line and the triple negative breast cancer (TNBC) cell line MDA-MB-
231. As shown in Figures 1a and 2a, Western blot analysis of whole-cell lysates from
the MCF10A, MCF7, and MDA-MB-231 cell lines with specific anti-EFHB (Figure 1) or
anti-SARAF (Figure 2) antibodies revealed the expression of EFHB and SARAF in the
cell lines investigated. Our results indicate that MCF10A expresses a low but detectable
amount of EFHB but, interestingly, MCF7 and MDA-MB-231 cells exhibit a significantly
greater expression (Figure 1a; p < 0.001 Kruskal–Wallis test combined with Dunn’s post
hoc test; n = 6). By contrast, the expression of SARAF was found to be similar in neoplastic
and pre-neoplastic cells (Figure 2a; n = 6).
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Figure 1. EFHB is expressed in breast cancer and pre-neoplastic epithelial cells and plays a relevant role in SOCE.
(a) MCF10A, MCF7, and MDA-MB-231 cells were lysed d analyzed using Western blotting with a specific anti-EFHB
antibody. The membrane was reprobed with an anti-β-actin antibody for protein loading control. Bar graphs represent EFHB
expression normalized to the β-actin content and expressed as percentage of the xp es ion in MCF10A cells. Molecular
masses indicated on the right were determined using molecular-mass markers run in the same gel. *** p < 0.001 compared
to EFHB expression in MCF10A cells. (b) MCF10A, MCF7, and MDA-MB-231 cells were transfected with shEFHB or
scramble plasmids (shRNAcv), as indicated. After 48 h cells were lysed and analyzed using Western blotting with an
anti-EFHB antibody, followed by reprobing with an anti-β-actin antibody for protein loading control. Bar graphs represent
EFHB expression normalized to the β-actin content at the different experimental conditions and expressed as percentage of
the expression in shRNAcv-treated cells (control). *** p < 0.001 compared to EFHB expression in shRNAcv-treated cells.
Uncropped Western blot figures in Figure S2. (c–h) MCF10A, MCF7, and MDA-MB-231 cells were transfected with shEFHB
or scramble plasmids (shRNAcv), as indicated. Forty-eight hours after transfection, cells were loaded with fura-2 and
perfused with a Ca2+-free medium (100 µM of EGTA was added). Cells were then stimulated with TG (2 µM) followed
by the reintroduction of external Ca2+ (final concentration of 1 mM) to initiate Ca2+ entry. Bar graphs represent TG-induced
Ca2+ release and entry in MCF10A (f), MCF7 (g) and MDA-MB-231 (h), expressed as fold change experimental over control
(shRNAcv-treated cells). Data are mean ± SEM of 40 cells/day/3–5 days. *** p < 0.001 compared to Ca2+ entry in control cells.
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SOCE in MCF7 and MDA-MB-231 cells has been reported to be strongly dependent on
STIM1 [9]; therefore, we have further explored the functional role of the STIM1 modulators,
EFHB and SARAF, in SOCE in these cell types, as compared to MCF10A breast epithelial
cells. To assess the role of EFHB in SOCE, MCF10A, MCF7, and MDA-MB-231 cells were
transfected with shRNA for EFHB [19] or scramble plasmids to analyze the effect of EFHB
knockdown on thapsigargin (TG)-evoked Ca2+ entry. As shown in Figure 1b, transfection
with shEFHB significantly attenuated the expression of the target protein by about 60–70%
in 48 h (p < 0.001; Mann–Whitney U test). As depicted in Figure 1c, in cells transfected
with scramble plasmids and suspended in a Ca2+-free medium, treatment with the SERCA
inhibitor TG (2 µM) resulted in a transient increase in the fura-2 fluorescence ratio due
to Ca2+ release from the intracellular Ca2+ stores. Subsequent addition of Ca2+ to the
extracellular medium resulted in a rise in the fura-2 fluorescence ratio indicative of a Ca2+
influx. Cell transfection with the shEFHB plasmid did not induce any significant effect
on the resting fura-2 fluorescence ratio (in ratio a.u.: MCF10A shRNAcv: 0.47 ± 0.08 vs.
shEFHB: 0.48 ± 0.09; MCF7 shRNAcv: 0.33 ± 0.06 vs. shEFHB: 0.36 ± 0.07; MDA-MB-231
shRNAcv: 0.33 ± 0.06 vs. shEFHB: 0.35 ± 0.06) or the rise in the ratio induced by TG
(Figure 1f–h), thus suggesting that EFHB knockdown does not alter the ability of the cells
to accumulate Ca2+ into the ER. In addition, these findings suggest that transfection of
the plasmid does not alter the Ca2+ leakage rate from the ER. EFHB knockdown does not
significantly modify SOCE in MCF10A, which is consistent with the low expression of
the protein in this cell type and indicates that EFHB does not play a relevant role in the
activation of SOCE in MCF10A cells (Figure 1c,f; n = 40 cells/day/3–5 days). By contrast,
attenuation of EFHB expression significantly reduced SOCE in breast cancer MCF7 and
MDA-MB-231 cells (Figure 1d,e,g,h; p < 0.001 Student’s t-test; n = 40 cells/day/3–5 days).
These findings indicate that EFHB plays a relevant role in the activation of SOCE in breast
cancer cells.
Furthermore, we have evaluated the role of SARAF in SOCE in MCF10A cells and
the cancer cell lines MCF7 and MDA-MB-231. To investigate this phenomenon, cells were
transfected with shSARAF or scramble plasmids, and the effect of SARAF knockdown in
SOCE was assessed by fluorescence microscopy. As shown in Figure 2b, transfection with
shSARAF significantly reduced the expression of SARAF by about 60–70% in 48 h (p < 0.001;
Mann–Whitney U test), depending on the cell type evaluated. Our results indicate that
SARAF knockdown did not significantly modify either the resting fura-2 fluorescence
ratio (in ratio a.u.: MCF10A shRNAcv: 0.47 ± 0.08 vs. shSARAF: 0.45 ± 0.06; MCF7
shRNAcv: 0.33 ± 0.06 vs. shSARAF: 0.35 ± 0.06; MDA-MB-231 shRNAcv: 0.33 ± 0.06
vs. shSARAF: 0.35 ± 0.07) or the rise in the Ca2+ signal induced by TG (Figure 2f–h).
The latter suggests that SARAF knockdown does not modify the ability of these cells
to accumulate Ca2+ into the ER, as previously described in SH-SY5Y [15] and MEG01
cells [16]; however, in HeLa cells, SARAF knockdown significantly enhanced the ER Ca2+
level [13]. SARAF knockdown significantly enhances SOCE in MCF10A and MDA-MB-231
cells (Figure 2c,e,f,h; n = 40 cells/day/3–5 days), which is compatible with a role of SARAF
in cells where SOCE is predominantly mediated by STIM1 and Orai1 [13,16]. By contrast,
attenuation of SARAF expression significantly reduced SOCE in breast cancer MCF7
cells, where SOCE is strongly dependent on STIM1, STIM2, and Orai3 [9] (Figure 2d,e,g,h;
p < 0.05–0.001 Student’s t test; n = 40 cells/day/3–5 days).
As SARAF is a well-known inhibitor of STIM1 and STIM2 [13], we have further tested
whether the effect of SARAF in SOCE and MCF7 cells is mediated by Orai1 or Orai3. To
address this phenomenon, we transfected cells with shOrai1, and shOrai1, in combina-
tion with shSARAF or scramble plasmids and SOCE, was determined as described above.
Our results indicate that Orai1 knockdown, alone or in combination with SARAF knock-
down, did not significantly modify the resting fura-2 fluorescence ratio (MCF7 shRNAcv:
0.35 ± 0.05 vs. shOrai1: 0.34 ± 0.06 or shOrai1+shSARAF: 0.36 ± 0.06) or Ca2+ release
from the intracellular stores (Figure 2i). As shown in Figure 2i, transfection of MCF7 cells
with shOrai1 did not significantly modify SOCE but did so in combination with shSARAF-
Cancers 2021, 13, 4160 6 of 16
attenuated SOCE, to a similar extent whereby SARAF knockdown was carried out alone
(Figure 2d,g; p < 0.001; n = 40 cells/day/3–5 days), which indicates that Orai1 is not
involved in SOCE in MCF7 cells and that the role of SARAF in MCF7 cells is independent
on Orai1. We have further evaluated the role of Orai3 on the SARAF-mediated response.
Cells were transfected with esiOrai3 (a pool of siRNA that target the Orai3 mRNA), alone
or in combination with shSARAF, or scramble plasmids and SOCE were determined as
described above. Our results indicate that SARAF and/or Orai3 knockdown did not sig-
nificantly modify the resting fura-2 fluorescence ratio (MCF7 shRNAcv: 0.33 ± 0.06 vs.
siOrai3: 0.35 ± 0.06 or siOrai3+shSARAF: 0.34 ± 0.06). Interestingly, as shown in Figure 2j,
the transfection of MCF7 cells with siOrai3 significantly attenuated SOCE by a similar
extent than transfection of shSARAF (Figure 2d,g) or the combination of both plasmids
(Figure 2j), thus suggesting that the role of SARAF in MCF7 cells is entirely mediated by
Orai3 (p < 0.001; n = 40 cells/day/3–5 days). Altogether, these findings indicate that SARAF
plays a negative regulatory role in SOCE in pre-neoplastic breast epithelial cells and TNBC
cells. By contrast, our results indicate that SARAF plays a positive role in SOCE in ER+
breast cancer cells.
To further explore the differential role of SARAF in different breast cancer subtypes,
we repeated the experiments in another ER+ and TNBC cell line, with T47D and MDA-MB-
468 cells, respectively. Our results indicate that SARAF knockdown significantly enhances
SOCE in T47D while suppressing SOCE in MDA-MB-468 cells, without having any effect on
the resting fura-2 fluorescence ratio or Ca2+ release from the intracellular stores (Figure S1;
p < 0.001; n = 40 cells/day/3–5 days). These findings confirm the differential role of SARAF
in SOCE in ER+ and TNBC cells.
2.2. EFHB and SARAF Are Required for Cell Viability in Breast Cancer Cells
Next, we have investigated the possible role of EFHB and SARAF in cell viability
in breast pre-neoplastic and neoplastic cells. To investigate this phenomenon, we have
explored the effect of cell transfection with shEFHB, shSARAF, or both on cell viability
by using the cell-permeant dye calcein and propidium iodide. As shown in Figure 3a,
our results indicate that all MCF10A cells show that calcein fluorescence and propidium
iodide staining were unaffected by EFHB knockdown (n = 6). However, attenuation
of EFHB expression in MCF7 and MDA-MB-231 cells significantly attenuated calcein
staining (p < 0.05; Mann–Whitney U test; n = 8) after 48 h. Consistently, EFHB knockdown
significantly enhanced propidium iodide staining (Figure 3a; p < 0.05; Mann–Whitney U
test; n = 8). These findings indicate that EFHB is specifically required for breast cancer
cell viability without affecting the viability of MCF10A cells. By contrast, attenuation
of SARAF expression significantly reduced the number of viable MCF10A, MCF7, and
MDA-MB-231 cells (Figure 3b; p < 0.05; Mann–Whitney U test; n = 8). The combined
knockdown of EFHB and SARAF did not result in an additive effect on cell viability
(Figure 3c; p < 0.05; Mann–Whitney U test; n = 8), thus suggesting that EFHB and SARAF
participate in the same intracellular pathway. These findings indicate that both EFHB
and SARAF are essential for MCF7 and MDA-MB-231 cell viability, while only SARAF is
required for MCF10A cell viability, which is consistent with the low expression of EFHB in
these cells.
We have further tested whether the dependence of cell viability on SARAF and EFHB
is reversible. To address this, phenomenon cells were co-transfected with shEFHB or
shSARAF in combination with EFHB or SARAF expression plasmids, respectively. As
shown in Figure 3a,b, overexpression of EFHB or SARAF in cells transfected with shEFHB
or shSARAF reversed the effect of EFHB and SARAF knockdown in cell viability, thus
indicating that the effects observed upon attenuation of EFHB and SARAF in cell viability
is reversible. In addition, these findings reveal that the effects observed with the shRNA
plasmids are specifically mediated by protein knockdown.
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2.3. EFHB and SARAF Are Required for Proliferation and Migration in Breast Cancer Cells but
Not in Pre-Neoplastic Epithelial Cells
It is well known that SOCE plays an important role in proliferation and migration in
breast cancer cells [20]. Hence, we have further investigated the effect of EFHB and SARAF
knockdown on the ability of MCF7 and MDA-MB-231 cells to proliferate and migrate.
Cells were transfected with shEFHB, shSARAF, or scramble plasmids and, after, 48-h cell
proliferation was assessed at time = 0 h, as well as 24, 48, and 72 h later. As shown in
Figure 4a, EFHB knockdown was without effect on MCF10A cell proliferation, at least for
the time investigated, which is compatible with the low expression of EFHB in these cells.
However, attenuation of EFHB expression significantly reduced MCF7 and MDA-MB-231
cell proliferation at all the times investigated, as compared with cells transfected with
scramble plasmids (p < 0.05 the Kruskal–Wallis test combined with Dunn’s post-hoc test;
n = 6). These findings indicate that EFHB plays a relevant role in proliferation specifically
in breast cancer cells without having a detectable role in pre-neoplastic cells. Similarly,
transfection of MCF7 and MDA-MB-231 with shSARAF resulted in a significant reduction in
cell proliferation compared to cells transfected with scramble plasmids (Figure 4b; p < 0.05
the Kruskal–Wallis test combined with Dunn’s post-hoc test; n = 6); however, SARAF
knockdown in MCF10A did not significantly alter cell proliferation. These findings suggest
that SARAF is required for breast neoplastic cell proliferation. Co-transfection of neoplastic
cells with shEFHB in combination with EFHB expression plasmid completely reversed the
effect of shEFHB (Figure 4a) and similar results were observed in cells transfected with
shSARAF and SARAF expression plasmid (Figure 4b), which indicates that the effect of
shEFHB and shSARAF transfection on cell proliferation is mediated by attenuation of the
protein expression.
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Thereafter, we transfected MCF10A, MCF7, and MDA-MB-231 cells with shEFHB,
shSARAF, or shRNAcv, as control, and analyzed cell cycle parameters. Cells serum de-
prived for 24 h were used as positive contr l (Figure 4c). We found th t MCF7 and
MDA-MB-231 cells transfected with shEFHB or shSARAF displ yed G1 arrest (Figure 4c;
p < 0.001). Similarly, serum-deprived cells also displayed a G1 arrest (Figure 4c). By
cont a t, EFHB or SARAF knockdown did not significantly ter MCF10A cell cycle pro-
gression (Figure 4c). These findings confirm the functional role of EFHB and SARAF in cell
proliferation and cell cycle progression.
We have also assessed the functional role of EFHB and SARAF on MCF10A, MCF7,
and MDA-MB-231 cells migration using the well-established wound healing assay [21].
Cells transfected with scramble plasmids significantly reduced the wound size during the
first 48 h (Figure 4c; p < 0.05 Mann–Whitney U test; n = 6). Transfection of MCF10A cells
with shEFHB did not significantly impair cell migration at least for 48 h (Figure 5a; n = 6),
which is attributed to the low EFHB expression in these cells. By contrast, EFHB knock-
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down significantly attenuated cell migration in MCF7 and MDA-MB-231 cells (Figure 5c,e;
p < 0.001; n = 6), thus suggesting that EFHB plays a relevant role in MCF7 and MDA-MB-
231 cells migration without affecting the ability of MCF10A cells to migrate. Similarly,
a reduction in SARAF expression had no impact in MCF10A cells migration (Figure 5b;
n = 6), whereas SARAF knockdown significantly impaired cell migration in MCF7 and
MDA-MB-231 cells (Figure 5d,f; p < 0.001 Mann–Whitney U test; n = 6). All together, our
data suggest that SARAF function is important for MCF7 and MDA-MB-231 cells migration.
As mentioned above, co-transfection with EFHB or SARAF expression plamids revesed the
inhibitory effect of EFHB and SARAF knockdown in cell migration (Figure 5c–f).
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3. Discussion
SOCE has been reported to play an essential role in the development of a variety of
breast cancer hallmarks, including cell viability, migration, proliferation, and apoptosis
resistance [22–25]. STIM1 and Orai1 are the key elements in SOCE but several proteins,
such as SARAF and EFHB, play an important role fine-tuning the amount of Ca2+ entering
the cell through the store-operated channels [13,14,16,17]. Here, we report that EFHB is
overexpressed in ER+ and TNBC cells compared to pre-neoplastic cells while neoplastic
and pre-neoplastic cells exhibit a similar expression of SARAF. In addition, both proteins
play an important role in the activation of SOCE in breast cancer cells. Our results further
indicate that EFHB and SARAF are required for breast cancer MCF7 and MDA-MB-231
cells viability, proliferation, and migration (Figure 6), although the signaling pathway
might differ between both cell types. In MCF7 cells, SARAF and EFHB play a positive
effect on SOCE, while in MDA-MB-231 cells, the SARAF and EFHB signalplex plays a
regulatory role in SOCE, thus preventing Ca2+ overload, as previously described in other
cellular models [13,14,26,27].
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Figure 6. Cartoon summarizing the functional role of SARAF and EFHB in ER+ and triple negative breast cancer (TNBC)
cells. In ER+ breast cancer cells and TNBC cells, SOCE is predominantly mediated by Orai3 and Orai1 channels, respectively.
SARAF and EFHB modulate STIM1 activation and function and fine-tune SOCE, resulting in adequate Ca2+ signals for cell
proliferation, migration, and viability.
Our findings reveal that SARAF knockdown significantly reduces SOCE in the ER+
breast cancer MCF7 cell line. To our knowledge, this is the first description of a predominant
positive role of SARAF in SOCE in a given cell type, but in a recent study we have reported
that SARAF and Orai1 are required for Ca2+ influx induced by VEGF in vascular endothelial
cells [18]. SOCE in MCF7, as well as in other ER+ breast cancer cell lines, exhibits significant
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phenotypic and functional differences compared to other cell types. For instance, while the
expression of STIM1 in these cells is normal or low, STIM2 expression is slightly higher, and
both Orai1 and Orai3 are overexpressed, especially Orai3 [9,10,28]. From the functional
point of view, SOCE in MCF7 is mediated by STIM1, STIM2, and Orai3, in contrast to
other breast cancer subtypes, such as TNBC cells, where SOCE is entirely dependent on
STIM1 and Orai1 [9,10]. In addition to its role in SOCE, STIM2 also plays a relevant role
in the maintenance of resting cytosolic and ER Ca2+ concentration in MCF7 cells [28].
SARAF has been described as a negative modulator of STIM1 and STIM2 but its possible
role on Orai3 function has not been elucidated. SARAF interacts with STIM1 at rest, to
prevent STIM1 spontaneous activation [13], and mediates STIM1 deoligomerization upon
Ca2+ store refilling, finally leading to SCDI [13,14]. Concerning STIM2, in HEK-293T cells,
SARAF modulates resting cytosolic and ER Ca2+ concentrations by inhibition of STIM2-
dependent basal SOCE [13]. Here, we show that knockdown of Orai3, SARAF, or both in
MCF7 cells results in a similar degree of inhibition of SOCE, which might indicate that
SARAF is necessary for the activation of Orai3 and thus SOCE in MCF7 cells, and suggests
that SARAF plays a positive role on Orai3 channel function.
Our results indicate that EFHB and SARAF are expressed in neoplastic and pre-
neoplastic cells. However, while the expression of SARAF is similar in breast cancer and
pre-neoplastic cells, EFHB expression is significantly greater in cancer cells. In a model
where SARAF plays an inhibitory role in STIM1 function [13,14,16,29] and EFHB transiently
releases STIM1 from SARAF, thus facilitating SOCE [19], one would expect that, if SARAF
is similarly expressed in cells of a given lineage, the expression of EFHB could make a
difference between the extent of SOCE in those cell types. This might be the case for
MCF10A, which exhibits the lowest EFHB expression and the smaller extent of SOCE
compared to MDA-MB-231 cells. Although we cannot rule out other functional differences
between these cell types, the relative different expression of EFHB might be, at least
partially, involved in the different extent of SOCE observed among the cells investigated.
4. Materials and Methods
4.1. Materials and Reagents
Fura-2 acetoxymethyl ester (fura-2/AM) was purchased from Molecular Probes
(Leiden, The Netherlands). Thapsigargin (TG), a rabbit polyclonal anti-β-actin antibody
(catalog number A2066, epitope: amino acids 365–375 of human β-actin), bovine serum
albumin (BSA), insulin (catalog number: I9278), epidermal growth factor (catalog number:
E9644), esiOrai3 (a pool of siRNAs that target the Orai3 mRNA), and cholera toxin (catalog
number: C8052) were purchased from Sigma-Aldrich (Madrid, Spain). A rabbit polyclonal
anti-TMEM66 (SARAF) antibody (catalog number PA5-24237, epitope amino acids 33–62
of the N-terminal region of human TMEM66), and a Live/Dead® viability/cytotoxicity
kit were purchased from Thermo Fisher (Madrid, Spain). DharmaFECT was purchased
from Dharmacon (Lafayette, CO, USA). A rabbit polyclonal anti-EFHB antibody (catalog
number AP10904a, epitope: amino acids 1–30 of human EFHB (N-terminal)) was purchased
from Abgent (San Diego, CA, USA). A horseradish peroxidase-conjugated anti-rabbit IgG
antibody was purchased from Jackson (Cambridge, UK). Enhanced chemiluminescence
detection reagents were from Pierce (Cheshire, UK). A bromodeoxyuridine (BrdU) cell pro-
liferation assay kit was purchased from BioVision (Milpitas, CA, USA). All other reagents
were of analytical grade.
4.2. Cell Culture and Transfections
The human breast epithelial MCF10A cell line was provided by Dr. Potier-Cartereau
(Université François Rabelais Tours, France). The breast cancer MCF7 and MDA-MB-231
cell lines were obtained from ATCC (Manassas, VA, USA), and cultured at 37 ◦C with a
5% CO2 in DMEM-F12 (MCF10A) or DMEM (MCF7 and MDA-MB-231), supplemented
with 10% (v/v) horse or fetal bovine serum, respectively, and 100 U/mL of penicillin
and streptomycin.
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For the knockdown expression of SARAF, a pLKO.1-puro plasmid-based shRNA tar-
geting the sequence CGGACTTAGATATTGCATACA (clone ID: TRCN0000146643; Sigma-
Aldrich) was used [16]. For the knockdown expression of EFHB, a pLKO.1-puro plasmid-
based shRNA targeting the sequence GCCAGAAGATATTGTCTTAAA (clone ID:
TRCN0000055578; Sigma-Aldrich) was used [19]. Cells were transfected with the shEFHB,
shSARAF, esiOrai3, or scramble plasmids, as described previously [16,19] using Dharma-
FECT transfection reagent, and were used 48 h after transfection. Plasmids were used for
silencing experiments at 1 µg/mL.
4.3. Determination of Cytosolic Free-Ca2+ Concentration
Cells were loaded with fura-2 by incubation with 5 µM of fura 2/AM (MCF10A) or
2 µM of fura 2/AM (MCF7 and MDA-MB-231) for 30 min at 37 ◦C. Coverslips with attached
cultured cells were mounted on a perfusion chamber and, subsequently, placed on the stage
of an epifluorescence inverted microscope (Nikon Eclipse Ti2, Amsterdam, The Nether-
lands) with image acquisition and analysis software (NIS-Elements Imaging Software
v.5.02.00, Nikon). Cells were superfused with HEPES-buffered saline (HBS) containing (in
mM) 125 NaCl, 5 KCl, 1 MgCl2, 5% glucose, 25 HEPES, and pH 7.4, supplemented with
0.1% (w/v) BSA. Samples were alternatively excited with light from a xenon lamp passed
through a high-speed monochromator (Optoscan ELE 450, Cairn Research, Faversham,
UK) at 340/380 nm. Fluorescence emission at 505 nm was detected using a sCMOS camera
(Zyla 4.2, Andor, Belfast, UK) and recorded using NIS-Elements AR software (Nikon,
Amsterdam, The Netherlands). A fluorescence ratio (F340/F380) was calculated pixel by
pixel [21] and was normalized to the ratio in resting cells (F/F0). TG-evoked Ca2+ release
and SOCE were measured as the integral of the rise in the fura-2 fluorescence ratio for 5
and 21/2 min, respectively, after the addition of TG or Ca2+, respectively.
4.4. Western Blotting
Western blotting was performed, as described previously. Briefly, cell lysates were
resolved by 10% SDS-PAGE and separated proteins were electrophoretically transferred
onto nitrocellulose membranes for subsequent probing. Blots were incubated overnight
with 10% (w/v) BSA in Tris-buffered saline with 0.1% Tween 20 (TBST) to block residual
protein binding sites. Immunodetection of EFHB, SARAF, and β-actin was achieved by
incubation overnight with the anti-SARAF or anti-EFHB antibodies diluted 1:1000 in TBST,
or by incubation for 1 h with an anti-β-actin antibody diluted 1:2000 in TBST. The primary
antibody was removed, and blots were washed six times for 5 min each with TBST. To
detect the primary antibody, blots were incubated for 1 h with horseradish peroxidase-
conjugated goat anti-rabbit IgG antibody diluted 1:10,000 in TBST and then exposed to
enhanced chemiluminescence reagents for 5 min. The density of bands was measured
using C-DiGit Chemiluminescent Western Blot Scanner and Fiji-ImageJ software (NIH,
Bethesda, MD, USA).
4.5. Cell Proliferation
Cells were seeded at a concentration of 5 × 103/well (MCF7 and MDA-MB-231) or
1 × 103/well (MCF10A) into 96-well plates and, after 0, 24, 48, and 72 h, cell proliferation
was assessed using a specific cell proliferation assay kit based on the measurement of
BrdU incorporation during DNA synthesis according to the manufacturer’s instructions
(BioVision). Absorbance in samples was measured using a plate reader (Epoch, Biotek,
Swindon, UK) at 450 nm and presented as arbitrary units.
4.6. Cell Viability Assay
Cell viability was assessed using a Live/Dead® viability/cytotoxicity kit as described
previously [30]. Briefly, cells were incubated for 45 min with 2 µM of calcein-AM and
4 µM of propidium iodide, as per the manufacturer’s instructions. Cells were washed
and resuspended in fresh HBS. Coverslips with attached cultured cells were mounted on
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a perfusion chamber and placed on the stage of an epifluorescence inverted microscope
(Nikon Eclipse Ti-2) with an image acquisition and analysis system (Nikon NIS-Elements
AR v.5.02.00). Samples were excited at 430 nm and 555 nm for calcein and propidium
iodide, respectively, and the resulting fluorescence was recorded at 542 nm (for viable cells)
and 624 nm (for dead cells).
4.7. Wound-Healing Assay
For wound healing assay, MCF10A, MCF7, and MDA-MB-231 cells were seeded in
a 35-mm 6-well multidish to obtain confluence after 24 h. Next, cells were cultured in
medium supplemented with 1% serum, and a wound was created using a sterile 200-µL
plastic pipette tip. Photographs were taken immediately or at the times indicated using an
EVOS FL auto 2 cell imaging system (ThermoFisher Scientific, Madrid, Spain). Migration
of cells was quantitated using Fiji ImageJ (NIH, Bethesda, MD, USA).
4.8. Determination of Cell Cycle by Flow Cytometry
Cell cycle was evaluated using propidium iodide (PI). Then, 48 h after transfection
or 24 h after serum deprivation, 2 × 106 cells were fixed with EtOH 70% at −20 ◦C for
12–24 h. Next, EtOH was removed and washed twice with fresh ice-cold PBS and the cells
were permeabilized with PBS containing 0.1% (v/v) Triton X-100 and 100 µg/mL RNAasa
at 37 ◦C for 15–30 min. The percentages of cell cycle stages were defined by incubating
propidium iodide (2 µM) at 37 ◦C for 30 min in darkness, as per the manufacturer’s
instructions. To analyze cell cycle status, cellular DNA content was estimated using
a FACS-SCAN flow cytometer (Becton Dickinson, Madrid, Spain). Forward and side
scattering were considered to select appropriated cells. The fluorescence emitted from cells
was acquired at a wavelength of 555/624 nm (Ex/Em) for PI.4.9.
Analysis of statistical significance was performed using the Kruskal–Wallis test com-
bined with Dunn’s post-hoc test (GraphPad Prism Windows 8, San Diego, CA, USA).
For comparison between two groups, the Mann–Whitney U test (or Student’s t-test for
the analysis of Ca2+ determinations) was used. A p-value < 0.05 was considered to be
statistically significant.
5. Conclusions
Our results indicate that SARAF and EFHB are expressed in breast cancer and pre-
neoplastic breast epithelial cells and play a relevant role in SOCE. While SARAF expression
is similar in neoplastic and pre-neoplastic cells, EFHB is overexpressed in breast cancer cells,
which might partially explain the enhanced SOCE observed in cancer cells. Cell viability,
proliferation, and migration is strongly dependent on SARAF and EFHB, or exclusively
SARAF, in breast cancer and pre-neoplastic cells, respectively, thus suggesting that these
proteins play an important role in breast cancer development and progression.
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.3390/cancers13164160/s1, Figure S1: Functional role of SARAF in Ca2+ release and SOCE in the ER+
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and 2a,b.
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